

Umberto Vitolo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1327610/umberto-vitolo-publications-by-year.pdf>

Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185 papers	9,779 citations	48 h-index	96 g-index
194 ext. papers	11,356 ext. citations	5.2 avg, IF	5.14 L-index

#	Paper	IF	Citations
185	Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2021 ,	2.2	5
184	A three-gene signature based on , and improves risk stratification in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021 , 106, 2405-2416	6.6	4
183	Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. <i>Blood Advances</i> , 2021 , 5, 1737-1745	7.8	0
182	Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. <i>Blood</i> , 2021 , 138, 213-220	2.2	7
181	End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. <i>Blood Advances</i> , 2021 , 5, 1283-1290	7.8	6
180	Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. <i>Hematological Oncology</i> , 2021 , 39, 293-303	1.3	4
179	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1317-1328	2.2	32
178	Antibody Therapies for Large B-Cell Lymphoma. <i>Biologics: Targets and Therapy</i> , 2021 , 15, 153-174	4.4	
177	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. <i>Leukemia</i> , 2021 , 35, 787-795	10.7	19
176	Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021 , 62, 999-1002	1.9	
175	BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 267-278.e10	2	1
174	Partial responses to ibrutinib in Waldenström macroglobulinaemia - good enough?. <i>British Journal of Haematology</i> , 2021 , 192, 423-424	4.5	1
173	A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021 , 193, 280-289	4.5	3
172	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021 , 8, e34-e44	14.6	9
171	Bcl-2 inhibition in DLBCL: "the times they are a-changing"?. <i>Blood</i> , 2021 , 137, 577-579	2.2	2
170	Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. <i>Leukemia</i> , 2021 ,	10.7	5
169	Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. <i>Blood Advances</i> , 2021 , 5, 2935-2944	7.8	0

168	Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. <i>Blood Advances</i> , 2021 , 5, 2945-2957	7.8	1
167	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2606-2609	4.4	1
166	Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in FL from 5,225 Patients on 13 Clinical Trials. <i>Blood</i> , 2021 ,	2.2	6
165	A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial.. <i>Cancers</i> , 2021 , 14,	6.6	1
164	Nonpegylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. <i>Hematological Oncology</i> , 2020 , 38, 478-486	1.3	6
163	A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 71	22.4	28
162	Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study. <i>American Journal of Hematology</i> , 2020 , 95, 749-758	7.1	8
161	The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments. <i>Annals of Hematology</i> , 2020 , 99, 277-282	3	5
160	Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. <i>Haematologica</i> , 2020 , 105, 2298-2307	6.6	15
159	Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice. <i>Expert Review of Hematology</i> , 2020 , 13, 851-869	2.8	1
158	Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020 , 105, e72-e75	6.6	5
157	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. <i>Leukemia and Lymphoma</i> , 2020 , 61, 318-327	1.9	5
156	Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA. <i>Blood Advances</i> , 2020 , 4, 1589-1593	7.8	9
155	High-grade B-cell lymphoma: how to diagnose and treat. <i>Expert Review of Hematology</i> , 2019 , 12, 497-506	6.8	5
154	Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. <i>Clinical Cancer Research</i> , 2019 , 25, 4634-4643	12.9	30
153	Monoclonal antibody-drug conjugates in B-cell lymphomas. <i>Lancet Haematology</i> , 2019 , 6, e232-e233	14.6	1
152	Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2019 , 185, 330-334	4.5	4
151	Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence. <i>Expert Review of Hematology</i> , 2019 , 12, 787-796	2.8	4

150	Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 4088-4088 ^{2,2}	7
149	Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?. <i>HemaSphere</i> , 2019 , 3, e284	0.3 7
148	Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. <i>British Journal of Haematology</i> , 2019 , 185, 940-944	4.5 30
147	Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. <i>Blood</i> , 2019 , 133, 919-926	2.2 44
146	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 229-240	40 283
145	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018 , 36, 624-632	1.3 36
144	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. <i>Haematologica</i> , 2018 , 103, 849-856	6.6 12
143	Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience. <i>Annals of Hematology</i> , 2018 , 97, 1619-1626	3 3
142	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2904-2910	1.9 5
141	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018 , 36, 561	1.3 38
140	Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era. <i>Lancet Oncology, The</i> , 2018 , 19, 162-163	21.7 4
139	A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma. <i>British Journal of Haematology</i> , 2018 , 183, 828-831	4.5 3
138	Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study. <i>British Journal of Haematology</i> , 2018 , 182, 453-456	4.5 3
137	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018 , 183, 35-46	4.5 6
136	Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma. <i>Lancet Oncology, The</i> , 2018 , 19, 1144-1146	21.7 1
135	Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification. <i>Blood</i> , 2018 , 132, 920-920	2.2 7
134	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 689-696	2.2 81
133	Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2405-2412	2.2 55

132	Histological transformation and secondary malignancies in follicular lymphoma. <i>Lancet Haematology, the</i> , 2018 , 5, e496-e497	14.6	1
131	Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. <i>Lancet Oncology, The</i> , 2018 , 19, 1449-1458	21.7	55
130	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , 2018 , 8, 63	7	9
129	The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study. <i>Leukemia and Lymphoma</i> , 2017 , 58, 226-229	1.9	4
128	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 552-560	2.2	69
127	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology, the</i> , 2017 , 4, e15-e23	14.6	75
126	Current options to manage Waldenström's macroglobulinemia. <i>Expert Review of Hematology</i> , 2017 , 10, 637-647	2.8	3
125	Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2017 , 76, 216-225	7.5	40
124	Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives. <i>Expert Review of Hematology</i> , 2017 , 10, 289-297	2.8	21
123	Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors'Reply. <i>Lancet Oncology, The</i> , 2017 , 18, e558	21.7	0
122	Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3529-3537	2.2	234
121	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1905-1912	2.2	98
120	Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study. <i>Leukemia Research</i> , 2017 , 61, 10-17	2.7	12
119	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2017 , 18, 1076-1088	21.7	72
118	Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2017 , 10, 697-705	2.8	24
117	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. <i>American Journal of Hematology</i> , 2017 , 92, 37-41	7.1	53
116	Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 14-22	2	13
115	Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL). <i>Thrombosis and Haemostasis</i> , 2017 , 117,	7	19

114	Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study. <i>Blood</i> , 2017 , 130, 824-824	2.2	11
113	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017 , 8, 79073-79086	3.3	38
112	Follicular Lymphoma: The Management of Elderly Patient. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017 , 9, e2017009	3.2	11
111	State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016 , 30, 1147-1162	3.1	9
110	G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony-stimulating factors (G-CSF) as observed in clinical practice in Italy. <i>Medical Oncology</i> , 2016 , 33, 139	3.7	5
109	Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2016 , 172, 879-88	4.5	25
108	Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. <i>British Journal of Haematology</i> , 2016 , 172, 111-21	4.5	14
107	Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1376-85	2.2	101
106	B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2016 , 57, 2375-81	1.9	5
105	Prognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 1239-43	4	18
104	Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 96-103	2	1
103	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2016 , 12, 1553-63	3.6	66
102	A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 38	22.4	26
101	Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2677-80	1.9	1
100	The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma). <i>Physica Medica</i> , 2016 , 32, 651-6	2.7	15
99	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology</i> , 2016 , 3, e467-e479	14.6	44
98	Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly. <i>British Journal of Haematology</i> , 2016 , 174, 160-2	4.5	6
97	Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma: experience with 27 patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 404-8	2	17

96	The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). <i>American Journal of Hematology</i> , 2015 , 90, 499-503	7.1	38
95	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 652-60	5.1	92
94	Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 75-85	2	24
93	The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 12-25	1.9	8
92	PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization. <i>Hematological Oncology</i> , 2015 , 33, 125-32	1.3	14
91	Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1671-6	1.9	17
90	Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2637-42	1.9	41
89	Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 507-13	2	11
88	Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. <i>British Journal of Haematology</i> , 2014 , 166, 69-76	4.5	32
87	[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1769-75	2.2	120
86	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , 2014 , 15, 730-7	21.7	135
85	Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 370-5	4	39
84	Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2564-71	1.9	9
83	Allogeneic stem cell transplant for adults with myelodysplastic syndromes: relevance of pre-transplant disease status. <i>Leukemia and Lymphoma</i> , 2014 , 55, 863-9	1.9	4
82	Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. <i>British Journal of Haematology</i> , 2014 , 164, 710-6	4.5	26
81	Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles. <i>Journal of Chemotherapy</i> , 2014 , 26, 315-20	2.3	3
80	Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. <i>Clinical Cancer Research</i> , 2014 , 20, 6398-405	12.9	69
79	Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. <i>Leukemia and Lymphoma</i> , 2014 , 55, 988-98	1.9	8

78	Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 87, 311-6	4	33
77	Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1183-7	1.9	37
76	The risk of CNS involvement in aggressive lymphomas in the rituximab era. <i>Expert Review of Hematology</i> , 2013 , 6, 643-52	2.8	1
75	Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 565-72	2.2	161
74	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013 , 24, 561-76	10.3	162
73	SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. <i>American Journal of Hematology</i> , 2013 , 88, 185-92	7.1	28
72	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. <i>Leukemia and Lymphoma</i> , 2013 , 54, 699-707	1.9	32
71	Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 231-4	2	21
70	R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1506-13	2.2	193
69	Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3351-9	2.2	48
68	Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. <i>Haematologica</i> , 2013 , 98, 1232-6	6.6	57
67	Lenalidomide in the treatment of lymphoproliferative disorders and multiple myeloma. <i>Advances in Hematology</i> , 2013 , 2013, 812605	1.5	1
66	XVI. CNS prophylaxis in aggressive lymphomas: for whom and how. <i>Hematological Oncology</i> , 2013 , 31 Suppl 1, 89-91	1.3	1
65	Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). <i>Blood</i> , 2013 , 122, 1137-43	2.2	95
64	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. <i>Blood</i> , 2013 , 122, 3759-66	2.2	63
63	Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2013 , 98, 1732-8	6.6	48
62	Core binding factor acute myeloid leukaemia and c-KIT mutations. <i>Oncology Reports</i> , 2013 , 29, 1867-72	3.5	23
61	Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. <i>Haematologica</i> , 2012 , 97, 416-22	6.6	58

60	Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. <i>Blood</i> , 2012 , 120, 3222-8	2.2	70
59	Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2012 , 53, 789-95	1.9	12
58	Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. <i>Blood</i> , 2012 , 119, 2066-73	2.2	186
57	Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation. <i>Cancer</i> , 2012 , 118, 3954-61	6.4	18
56	RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and unclassifiable highly aggressive B-cell lymphoma. <i>British Journal of Haematology</i> , 2012 , 156, 234-44	4.5	57
55	Lenalidomide in diffuse large B-cell lymphomas. <i>Advances in Hematology</i> , 2012 , 2012, 498342	1.5	10
54	Role of Positron Emission Tomography (PET/CT) in Primary Mediastinal Large B Cell Lymphoma (PMLBCL): Preliminary Results of an International Phase II Trial (IELSG-26 Study) Conducted On Behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1566-1566	2.2	2
53	Rituximab Dose-Dense Chemotherapy Followed by Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Significantly Reduces the Risk of Progression Compared to Standard Rituximab Dose-Dense Chemotherapy As First Line Treatment in Young Patients with High-Risk (as ID125) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results of Phase II Trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1566-1566	2.2	14
52	Update in indolent non-Hodgkin lymphoma (NHL): paradigm for Waldenström's macroglobulinemia (WM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 149-51	2	5
51	The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2011 , 117, 2405-13	2.2	28
50	The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens. <i>Cancer</i> , 2011 , 117, 1884-90	6.4	13
49	First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2766-72	2.2	135
48	ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. <i>New England Journal of Medicine</i> , 2011 , 365, 203-12	59.2	282
47	Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4227-33	2.2	38
46	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2226-36	1.9	27
45	Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000). <i>Blood</i> , 2011 , 118, 3704-3704	2.2	3
44	Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL). <i>Blood</i> , 2011 , 118, 777-777	2.2	4
43	Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. <i>Intensive Care Medicine</i> , 2010 , 36, 1666-74	14.5	112

42	Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin) is an effective salvage regimen in patients with relapsed or refractory lymphoma. <i>Cancer</i> , 2010 , 116, 4573-9	6.4	24
41	Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology. <i>American Journal of Hematology</i> , 2010 , 85, 147-55	7.1	5
40	Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers. <i>Blood</i> , 2010 , 116, 966-966	2.2	3
39	Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4555-62	2.2	483
38	Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. <i>British Journal of Haematology</i> , 2009 , 144, 367-75	4.5	50
37	Long term outcome of localized aggressive non-Hodgkin lymphoma treated with a short weekly chemotherapy regimen (doxorubicin, cyclophosphamide, bleomycin, vincristine, and prednisone) and involved field radiotherapy: result of a Gruppo Italiano Multiregionale per lo Studio dei Linfomi (GITMO) trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1475-84	1.9	1
36	Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. <i>Haematologica</i> , 2009 , 94, 1250-8	6.6	56
35	Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5156-64	2.2	378
34	Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established. <i>Future Oncology</i> , 2008 , 4, 199-210	3.6	2
33	Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Society of Bone Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1261-71	6.6	58
32	Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. <i>Blood</i> , 2008 , 111, 4004-13	2.2	200
31	Primary testicular lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 65, 183-9	7	82
30	A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. <i>Cancer</i> , 2008 , 112, 856-62	6.4	41
29	Follicular lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 66, 248-61	7	37
28	Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 67, 172-85	7	61
27	Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial. <i>Blood</i> , 2008 , 112, 834-834	2.2	1
26	Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. <i>Annals of Hematology</i> , 2007 , 86, 897-903	3	86
25	Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3746-52	2.2	667

24	High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. <i>Cancer Treatment Reviews</i> , 2007 , 33, 338-46	14.4	73
23	Radioimmunotherapy (RIT) with 90Y-Ibritumomab Tiuxetan (Zevalin) for the Treatment of Relapsed or Resistant Aggressive Diffuse Large B-Cell Lymphoma (DLBCL) Heavily Pretreated with Rituximab + Chemotherapy: A GIMURELL Experience.. <i>Blood</i> , 2007 , 110, 4478-4478	2.2	3
22	Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1590-6	2.2	65
21	Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study.. <i>Blood</i> , 2006 , 108, 208-208	2.2	4
20	Rituximab as Adjuvant to Dose-Dense and High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as First Line Treatment in Stage III/IV Diffuse Large B-Cell Lymphoma (DLBCL) at Poor Prognosis: Final Analysis of Phase II GIMURELL Trial.. <i>Blood</i> , 2006 , 108, 329-329	2.2	2
19	Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2006 , 91, 96-103	6.6	28
18	The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. <i>Haematologica</i> , 2006 , 91, 475-81	6.6	190
17	ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9198-207	2.2	144
16	Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas. <i>American Journal of Clinical Pathology</i> , 2005 , 124, 182-90	1.9	4
15	High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. <i>Haematologica</i> , 2005 , 90, 793-801	6.6	29
14	Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2005 , 90, 1236-57	6.6	28
13	Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linfomi. <i>Cancer</i> , 2004 , 101, 1601-8	6.4	39
12	A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2004 , 5, 50-5		28
11	Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. <i>Blood</i> , 2004 , 103, 2474-9	2.2	460
10	Follicular lymphoma international prognostic index. <i>Blood</i> , 2004 , 104, 1258-65	2.2	1348
9	Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. <i>Experimental Hematology</i> , 2003 , 31, 784-8	3.1	12
8	High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. <i>Cancer</i> , 2003 , 97, 2748-59	6.4	62
7	Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2003 , 107, 958-61	7.5	8

6	The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1911-7	1.9	19
5	High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Blood</i> , 2002 , 100, 1559-65	2.2	80
4	Most immunoglobulin heavy chain switch mu rearrangements in B-cell chronic lymphocytic leukemia are internal deletions. <i>FEBS Letters</i> , 2002 , 518, 119-23	3.8	10
3	Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001 , 114, 333-41	4.5	30
2	MACOP-B treatment for advanced stage diffuse large cell lymphoma: a multicenter Italian Study. <i>European Journal of Cancer & Clinical Oncology</i> , 1989 , 25, 1441-9		10
1	Predictive value of the early response to chemotherapy in high-risk stages II and III Hodgkin's disease. <i>Cancer</i> , 1987 , 60, 1713-9	6.4	19